ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2011
[Researche advances on CIK cells and their clinical use in lung cancer].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic value of immune-inflammation and nutritional indices in advanced hepatocellular carcinoma patients receiving immunotherapy with compound Kushen injection.World journal of gastrointestinal oncology · 2025Article
- Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.Medical oncology (Northwood, London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the leading cause of cancer-related death among human beings, lung cancer seriously threats peoples' health all over the world. Cytokine-induced killer cells (CIK) is a new kind of adaptive immune cells characterized by its dramatic proliferation ability and cytotoxicity, non-major histocompatibility antigens (MHC) restriction and low side effects, which draw an increasing attention in recent years. The review is to introduce the basic features and mechanism of CIK cells briefly and summarize the researches of CIK cells used in the clinical therapy for lung cancer. Finally, we discuss several problems that should be addressed before CIK cells are widely applied to clinical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.